Diabetic Retinopathy News and Research

RSS
In the initial stages, people with diabetic retinopathy may not notice their vision changing. Diabetics sometimes experience rapid changes in blood sugar that can temporarily cause blurry vision even when retinopathy is not present. If a person notices a few specks or spots floating in his visual field, this may mean he has developed proliferative diabetic retinopathy, the growth of abnormal new blood vessels on the retina and optic nerve. High blood sugar levels have been linked in studies to retinal blood vessel abnormalities. Blurred vision may occur when the macula--the small area at the center of the retina--swells as it fills with fluid that has leaked from retinal blood vessels. Because damage to the eye often develops slowly, early detection of diabetes and control of blood sugar through diet and medications can make a crucial difference in saving vision.

Effective diabetic retinopathy treatments include laser photocoagulation for early to moderate stages and a microsurgery called vitrectomy for repair of eyes with extensive damage. Injectable and oral medications that act on abnormal blood vessels to control diabetic retinopathy before vision loss occurs are now in development. Early detection would be key to the effectiveness of these treatments, also.
Study suggests race-specific cutoff points for a diabetes diagnostic test

Study suggests race-specific cutoff points for a diabetes diagnostic test

New compound effective at blocking damage to the retina in diabetic retinopathy

New compound effective at blocking damage to the retina in diabetic retinopathy

RPB awards $110,000 grant to Mass. Eye and Ear and HMS for research into blinding diseases

RPB awards $110,000 grant to Mass. Eye and Ear and HMS for research into blinding diseases

Otsuka, Acucela commence rebamipide ophthalmic suspension Phase 3 trial in dry eye syndrome

Otsuka, Acucela commence rebamipide ophthalmic suspension Phase 3 trial in dry eye syndrome

Ampio announces results from Optina trial on DME

Ampio announces results from Optina trial on DME

NIH awards Sirnaomics SBIR grant for developing STP705 siRNA wound healing product

NIH awards Sirnaomics SBIR grant for developing STP705 siRNA wound healing product

Diabetic Neuropathy: An interview with Dr Brian Callaghan

Diabetic Neuropathy: An interview with Dr Brian Callaghan

Researchers hope to use experiences of people with long-term T1D to benefit others

Researchers hope to use experiences of people with long-term T1D to benefit others

Thiazolidinedione drugs linked with increased risk of DME in patients with Type 2 diabetes

Thiazolidinedione drugs linked with increased risk of DME in patients with Type 2 diabetes

Ampio’s CRO completes Optina clinical trial for DME

Ampio’s CRO completes Optina clinical trial for DME

Nrf2-KEAP1 protein may play a role in diabetic retinopathy

Nrf2-KEAP1 protein may play a role in diabetic retinopathy

BioInvent, ThromboGenics to regain global rights to TB-403 from Roche

BioInvent, ThromboGenics to regain global rights to TB-403 from Roche

Ancient berry could protect against diabetic retinopathy

Ancient berry could protect against diabetic retinopathy

Cellular-level images of the living eye

Cellular-level images of the living eye

New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy

New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy

Screening for diabetic retinopathy once every two years maybe safe, cost-effective

Screening for diabetic retinopathy once every two years maybe safe, cost-effective

IRIDEX launches non-invasive MicroPulse Laser Trabeculoplasty for glaucoma

IRIDEX launches non-invasive MicroPulse Laser Trabeculoplasty for glaucoma

NEI awards Scripps Research $10.2M grant to develop new treatments for vision disorders

NEI awards Scripps Research $10.2M grant to develop new treatments for vision disorders

Regenerative medicine research offers hope for the blind

Regenerative medicine research offers hope for the blind

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.